UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000005739
Receipt No. R000006758
Scientific Title Phase ll trial of TS-1 + CDDP + Trastuzumab(SPT)-3 weekly schedule in HER2-positive advanced gastric cancer(HERBIS-1A) (OGSG 1101)
Date of disclosure of the study information 2011/06/10
Last modified on 2020/01/22 21:34:52

No. Disposal Last modified on Item of update
1 Insert 2011/06/07 23:30:24
2 Update 2011/08/10 18:49:12 Post marketing survey by drug manufacture etc., specified by Japanese law.
3 Update 2011/08/10 18:50:33 Recruitment status
4 Update 2011/08/10 18:51:48 Public title
5 Update 2011/08/11 17:35:08 Public title
6 Update 2011/11/11 18:33:09 Acronym
7 Update 2011/11/22 19:16:18 Anticipated trial start date
Last follow-up date
8 Update 2012/06/24 22:45:29 Public title
Public title
Acronym
Acronym
9 Update 2012/06/24 22:46:04 Recruitment status
10 Update 2012/06/24 22:49:10 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
11 Update 2012/07/09 23:12:25 Public title
Public title
Acronym
Acronym
12 Update 2012/12/07 21:28:03 Last follow-up date
13 Update 2013/06/09 21:53:04 Anticipated trial start date
Last follow-up date
14 Update 2013/06/09 21:58:18 Anticipated trial start date
Last follow-up date
15 Update 2014/12/16 21:43:35 Recruitment status
16 Update 2015/06/11 23:37:54 TEL
Email
TEL
Email
17 Update 2016/10/19 22:48:06 Email
Name of primary sponsor
Organization
18 Update 2017/02/12 23:56:39 URL releasing protocol
Publication of results
19 Update 2018/04/30 23:26:12 Email
20 Update 2018/04/30 23:33:44 Results
Results
21 Update 2018/05/10 20:27:17 Email
22 Update 2020/01/05 14:33:53 Date of IRB
23 Update 2020/01/05 14:48:38 URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
24 Update 2020/01/05 18:10:48 URL releasing protocol
Results
Results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
25 Update 2020/01/22 21:34:52 Date of IRB


Contact us.